Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.

Domalaon R, Berry L, Tays Q, Zhanel GG, Schweizer F.

Bioorg Chem. 2018 Oct;80:639-648. doi: 10.1016/j.bioorg.2018.07.018. Epub 2018 Jul 19.

PMID:
30053708
2.

Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria.

Domalaon R, Brizuela M, Eisner B, Findlay B, Zhanel GG, Schweizer F.

Amino Acids. 2019 Mar;51(3):383-393. doi: 10.1007/s00726-018-2673-9. Epub 2018 Nov 3.

PMID:
30392097
3.

Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics.

Vaara M.

Molecules. 2019 Jan 11;24(2). pii: E249. doi: 10.3390/molecules24020249. Review.

4.

MCR-1 Inhibition with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Sensitivity to Polymyxin in Escherichia coli.

Daly SM, Sturge CR, Felder-Scott CF, Geller BL, Greenberg DE.

MBio. 2017 Nov 7;8(6). pii: e01315-17. doi: 10.1128/mBio.01315-17.

5.

Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria.

Olaitan AO, Morand S, Rolain JM.

Front Microbiol. 2014 Nov 26;5:643. doi: 10.3389/fmicb.2014.00643. eCollection 2014. Review.

6.

Comparative Metabolomics and Transcriptomics Reveal Multiple Pathways Associated with Polymyxin Killing in Pseudomonas aeruginosa.

Han ML, Zhu Y, Creek DJ, Lin YW, Gutu AD, Hertzog P, Purcell T, Shen HH, Moskowitz SM, Velkov T, Li J.

mSystems. 2019 Jan 8;4(1). pii: e00149-18. doi: 10.1128/mSystems.00149-18. eCollection 2019 Jan-Feb.

7.

Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.

Schneider-Futschik EK, Paulin OKA, Hoyer D, Roberts KD, Ziogas J, Baker MA, Karas J, Li J, Velkov T.

ACS Infect Dis. 2018 May 11;4(5):646-655. doi: 10.1021/acsinfecdis.7b00238. Epub 2018 Apr 2.

8.

Polymyxin B3-Tobramycin Hybrids with Pseudomonas aeruginosa-Selective Antibacterial Activity and Strong Potentiation of Rifampicin, Minocycline, and Vancomycin.

Domalaon R, Yang X, Lyu Y, Zhanel GG, Schweizer F.

ACS Infect Dis. 2017 Dec 8;3(12):941-954. doi: 10.1021/acsinfecdis.7b00145. Epub 2017 Oct 27.

PMID:
29045123
9.

Structure-Function Studies of Polymyxin B Lipononapeptides.

Gallardo-Godoy A, Hansford KA, Muldoon C, Becker B, Elliott AG, Huang JX, Pelingon R, Butler MS, Blaskovich MAT, Cooper MA.

Molecules. 2019 Feb 2;24(3). pii: E553. doi: 10.3390/molecules24030553.

10.

Inhibition of the ATP Synthase Eliminates the Intrinsic Resistance of Staphylococcus aureus towards Polymyxins.

Vestergaard M, Nøhr-Meldgaard K, Bojer MS, Krogsgård Nielsen C, Meyer RL, Slavetinsky C, Peschel A, Ingmer H.

MBio. 2017 Sep 5;8(5). pii: e01114-17. doi: 10.1128/mBio.01114-17.

11.

Polymyxin-Induced Lipid A Deacylation in Pseudomonas aeruginosa Perturbs Polymyxin Penetration and Confers High-Level Resistance.

Han ML, Velkov T, Zhu Y, Roberts KD, Le Brun AP, Chow SH, Gutu AD, Moskowitz SM, Shen HH, Li J.

ACS Chem Biol. 2018 Jan 19;13(1):121-130. doi: 10.1021/acschembio.7b00836. Epub 2017 Dec 11.

PMID:
29182311
12.

Rediscovering the octapeptins.

Velkov T, Roberts KD, Li J.

Nat Prod Rep. 2017 Mar 17;34(3):295-309. doi: 10.1039/c6np00113k. Review.

13.

A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes.

Velkov T, Yun B, Schneider EK, Azad MA, Dolezal O, Morris FC, Nation RL, Wang J, Chen K, Yu HH, Wang L, Thompson PE, Roberts KD, Li J.

ACS Infect Dis. 2016 May 13;2(5):341-51. doi: 10.1021/acsinfecdis.6b00031. Epub 2016 Mar 29.

14.

Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.

Velkov T, Roberts KD, Nation RL, Wang J, Thompson PE, Li J.

ACS Chem Biol. 2014 May 16;9(5):1172-7. doi: 10.1021/cb500080r. Epub 2014 Mar 17.

15.

Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens.

Tran TB, Wang J, Doi Y, Velkov T, Bergen PJ, Li J.

Front Microbiol. 2018 Apr 12;9:721. doi: 10.3389/fmicb.2018.00721. eCollection 2018.

16.

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.

Evans ME, Feola DJ, Rapp RP.

Ann Pharmacother. 1999 Sep;33(9):960-7. Review.

PMID:
10492501
17.

Agents of Last Resort: Polymyxin Resistance.

Kaye KS, Pogue JM, Tran TB, Nation RL, Li J.

Infect Dis Clin North Am. 2016 Jun;30(2):391-414. doi: 10.1016/j.idc.2016.02.005. Review.

PMID:
27208765
18.

Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.

Velkov T, Roberts KD, Nation RL, Thompson PE, Li J.

Future Microbiol. 2013 Jun;8(6):711-24. doi: 10.2217/fmb.13.39. Review.

19.

Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?

Blaskovich MAT, Pitt ME, Elliott AG, Cooper MA.

Expert Rev Anti Infect Ther. 2018 Jun;16(6):485-499. doi: 10.1080/14787210.2018.1483240. Epub 2018 Jun 26. Review.

PMID:
29848132
20.

Binding of polymyxin B nonapeptide to gram-negative bacteria.

Vaara M, Viljanen P.

Antimicrob Agents Chemother. 1985 Apr;27(4):548-54.

Supplemental Content

Support Center